All Stories

  1. The Diligent Lego Player with Talocalcaneal Callosities
  2. The ECHO recommendations for dealing with vinblastine shortage affecting standard treatment of systemic Langerhans cell histiocytosis
  3. Therapiestrategien bei Kindern und Jugendlichen mit Langerhanszell Histiozytosen
  4. Aktualisierte AWMF Leitlinie zur Diagnostik und Therapie der Langerhanszell Histiozytose (LCH) im Kindes- und Jugendalter
  5. Clinicogenomic associations in childhood Langerhans cell histiocytosis: an international cohort study
  6. Outcome of haematopoietic cell transplantation in children with lysosomal acid lipase deficiency: a study on behalf of the EBMT Inborn Errors Working Party
  7. Essential medicines for childhood cancer in Europe: a pan-European, systematic analysis by SIOPE
  8. Concurrence of a kinase‐dead BRAF and an oncogenic KRAS gain‐of‐function mutation in juvenile xanthogranuloma
  9. Whole‐body magnetic resonance imaging for staging Langerhans cell histiocytosis in children and young adults
  10. Fröschlein im Mund: eine Blickdiagnose?
  11. SARS-CoV-2 Associated Pediatric Inflammatory Multisystem Syndrome With a High Prevalence of Myocarditis – A Multicenter Evaluation of Clinical and Laboratory Characteristics, Treatment and Outcome
  12. Vemurafenib acts as a molecular on-off switch governing systemic inflammation in Langerhans cell histiocytosis
  13. Additive Prognostic Impact of Gastrointestinal Involvement in Severe Multisystem Langerhans Cell Histiocytosis
  14. Training von Basisreanimationsmaßnahmen (Newborn Life Support, Paediatric Basic Life Support)
  15. EVOLUTION OF TREATMENT OF CHILDREN WITH LANGERHANS CELL HISTIOCYTOSIS
  16. Langerhans Cell Histiocytosis of the Orbit: Spectrum of Clinical and Imaging Findings
  17. Novel Compound Heterozygous Mutations in Two Families With Bernard–Soulier Syndrome
  18. Stem cell transplantation for children with hemophagocytic lymphohistiocytosis: results from the HLH-2004 study
  19. Hemolytic anemia due to the unstable hemoglobin Wien: manifestations and long-term course in the largest pedigree identified to date
  20. The coming of age of Langerhans cell histiocytosis
  21. Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study
  22. Epigenomics and Single-Cell Sequencing Define a Developmental Hierarchy in Langerhans Cell Histiocytosis
  23. Low mortality and short‐term morbidity in very preterm infants in Austria 2011–2016
  24. Mycoplasma-pneumoniae -assoziierte Mukositis mit Hautbeteiligung - ein Fallbericht
  25. Successful Treatment with SCIG of a Child with Refractory Chronic ITP
  26. Mycoplasma pneumoniae -associated mucositis with cutaneous involvement - a case report
  27. Longitudinal assessment of peripheral blood BRAFV600E levels in patients with Langerhans cell histiocytosis
  28. Langerhans cell histiocytosis in children
  29. Langerhans cell histiocytosis in children
  30. An update on the treatment of pediatric-onset Langerhans cell histiocytosis through pharmacotherapy
  31. Histiozytäre Erkrankungen
  32. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study
  33. Effective Immunological Guidance of Genetic Analyses Including Exome Sequencing in Patients Evaluated for Hemophagocytic Lymphohistiocytosis
  34. A consensus review on malignancy-associated hemophagocytic lymphohistiocytosis in adults
  35. Central Nervous System Langerhans Cell Histiocytosis
  36. Targeted inhibition of the MAPK pathway: emerging salvage option for progressive life-threatening multisystem LCH
  37. The Non-Langerhans Cell Histiocytoses (Rare Histiocytoses) – Clinical Aspects and Therapeutic Approaches
  38. Insights into the pathogenesis of Langerhans cell histiocytosis
  39. Current treatment of Langerhans cell histiocytosis
  40. Management of chronic immune thrombocytopenia in children and adolescents: lessons from an Austrian national cross-sectional study of 81 patients
  41. Two Novel Missense Mutations and a 5bp Deletion in the Erythroid-Specific Promoter of thePKLRGene in Two Unrelated Patients With Pyruvate Kinase Deficient Transfusion-Dependent Chronic Nonspherocytic Hemolytic Anemia
  42. Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study
  43. Malignancy-associated haemophagocytic lymphohistiocytosis in children and adolescents
  44. Treatment of Langerhans cell histiocytosis: it is time to learn from the past
  45. Lack of bone lesions at diagnosis is associated with inferior outcome in multisystem langerhans cell histiocytosis of childhood
  46. Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel
  47. Polycythaemia-inducing mutations in the erythropoietin receptor (EPOR): mechanism and function as elucidated by epidermal growth factor receptor-EPOR chimeras
  48. Histiozytosen
  49. Genetic Basis of Congenital Erythrocytosis
  50. Sequential decisions on FAS sequencing guided by biomarkers in patients with lymphoproliferation and autoimmune cytopenia
  51. Hypertrophic Obstructive Cardiomyopathy in an Infant With an Adrenocortical Tumor
  52. Radiological features of thymic langerhans cell histiocytosis
  53. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis
  54. Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens
  55. Ferritin concentrations correlate to outcome of hematopoietic stem cell transplantation but do not serve as biomarker of graft-versus-host disease
  56. Stem cell transplantation after reduced-intensity conditioning for sickle cell disease
  57. Notch is active in Langerhans cell histiocytosis and confers pathognomonic features on dendritic cells
  58. Langerhans cell histiocytosis (LCH): Guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years
  59. Isolated cutaneous Langerhans cell histiocytosis in a premature baby: What is the optimal approach?
  60. Langerhans-Zell-Histiozytose
  61. Pulmonary Involvement in Pediatric-Onset Multisystem Langerhans Cell Histiocytosis: Effect on Course and Outcome
  62. Langerhans cell histiocytosis: pragmatic empirism on the road to rational cure
  63. Long‐term outcome of hypothalamic pituitary tumors in Langerhans cell histiocytosis
  64. Kopf- und Halstumore im Kindesalter
  65. Newly diagnosed immune thrombocytopenia in children and adults: a comparative prospective observational registry of the Intercontinental Cooperative Immune Thrombocytopenia Study Group
  66. Variant alleles of cytokine genes influence risk and clinical course of Langerhans cell histiocytosis
  67. Multisystem Langerhans Cell Histiocytosis in Children
  68. Clinical and immunological overlap between autoimmune lymphoproliferative syndrome and common variable immunodeficiency
  69. Evaluating Bleeding Severity in Children with newly Diagnosed Immune Thrombocytopenia: A Pilot Study
  70. Novel TMPRSS6 mutations associated with iron-refractory iron deficiency anemia (IRIDA)
  71. Transcobalamin II deficiency at birth
  72. Subcutaneous anti-d globulin application is a safe treatment option of immune thrombocytopenia in children
  73. Diabetes insipidus in Langerhans cell histiocytosis: When is treatment indicated?
  74. Granulocyte Transfusions in Children and Young Adults
  75. A Syndrome with Congenital Neutropenia and Mutations inG6PC3
  76. Reactivations in Multisystem Langerhans Cell Histiocytosis: Data of the International LCH Registry
  77. Clinical and molecular characterisation of a prospectively collected cohort of children and adolescents with polycythemia vera
  78. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification
  79. Bone marrow assessment in Langerhans cell histiocytosis
  80. Extramedullary plasmacytoma of the adenoids
  81. Importance of allogeneic T-cells for disease control after stem cell transplantation for high-risk Langerhans cell histiocytosis
  82. Severe Anemia Owing to Occult Pulmonary Hemorrhage
  83. Central nervous system‐related permanent consequences in patients with Langerhans cell histiocytosis
  84. Critical issues concerning splenectomy for chronic idiopathic thrombocytopenic purpura in childhood
  85. Skelettbefall bei Langerhanszellhistiozytose
  86. Central diabetes insipidus: Is it Langerhans cell histiocytosis of the pituitary stalk? A diagnostic pitfall
  87. Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning
  88. Modern Imaging Methods for the Assessment of Langerhans' Cell Histiocytosis—Associated Neurodegenerative Syndrome: Case Report
  89. Risk factors for diabetes insipidus in langerhans cell histiocytosis
  90. Histiocytosis following T-acute lymphoblastic leukemia: A BFM study
  91. Langerhans cell histiocytosis in neonates
  92. Pineal gland abnormalities in Langerhans cell histiocytosis
  93. Central diabetes insipidus as presenting symptom of Langerhans cell histiocytosis
  94. Course and clinical impact of magnetic resonance imaging findings in diabetes insipidus associated with Langerhans cell histiocytosis
  95. Demonstration of CD1a positive cells in the cerebrospinal fluid—A clue to diagnosis of isolated Langerhans cell histiocytosis of the hypothalamic—pituitary axis?
  96. IVIG Treatment of Adenovirus Infection-Associated Macrophage Activation Syndrome in a Two-Year-Old Boy: Case Report and Review of the Literature
  97. Immunosuppressive treatment for chemotherapy-resistant multisystem langerhans cell histiocytosis
  98. IVIG Treatment of Adenovirus Infection-Associated Macrophage Activation Syndrome in a Two-Year-Old Boy: Case Report and Review of the Literature
  99. Response to initial treatment of multisystem langerhans cell histiocytosis: An important prognostic indicator
  100. Pattern and course of single-system disease in Langerhans cell histiocytosis data from the DAL-HX 83- and 90-study
  101. Statement of current majority practices in graft-versus-host disease prophylaxis and treatment in children
  102. Treatment of Multisystem Langerhans Cell Histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 Studies
  103. Cyclosporine A therapy for multisystem Langerhans cell histiocytosis
  104. Cyclosporine A therapy for multisystem Langerhans cell histiocytosis
  105. Leucocyte transfusions from rhG-CSF or prednisolone stimulated donors for treatment of severe infections in immunocompromised neutropenic patients
  106. OCCURRENCE OF ACUTE NONLYMPHOBLASTIC LEUKEMIA IN TWO GIRLS AFTER TREATMENT OF RECURRENT, DISSEMINATED LANGERHANS CELL HISTIOCYTOSIS
  107. Transplantation activities and treatment strategies in paediatric stem cell transplantation centres: a report from the EBMT Working Party on Paediatric Diseases
  108. A single Centre Experience with allogeneic Stem Cell Transplantation for Severe Aplastic Anaemia in Childhood